ALPHA-BLUE-OCEAN
25.4.2024 16:01:28 CEST | Business Wire | Press release
Environmental Performance Financing (EPF), a subsidiary of the Alpha Blue Ocean group, is proud to announce its collaboration with Europlasma (ALEUP:FP), a leader in depollution, material recovery, and decarbonation solutions, for the establishment of a bond financing arrangement.
This financing aims to support the Group's growth and development, particularly in key initiatives such as:
- The acquisition of MG-Valdunes: Europlasma has obtained the green light for the acquisition of MG-Valdunes' business assets, a crucial step towards strengthening industrial sovereignty and relaunching Valdunes' historic activities.
- The development of the Forges de Tarbes: Funds will also be allocated to increasing the production capacities of the Forges de Tarbes, which are facing growing demand, particularly in the defense sector.
- The continued development of historical activities: A significant portion of the funds will be dedicated to the ongoing development of depollution, decarbonation, and hazardous waste recovery activities, a domain in which Europlasma has excelled for years.
This partnership will strengthen Europlasma's market position while contributing to the achievement of essential environmental objectives.
This collaboration illustrates ABO Group's commitment to financing innovative and sustainable environmental projects.
Pierre Vannineuse, CIO and Founder of Alpha Blue Ocean: "We are delighted to announce the renewal of our partnership with Europlasma for a 7th significant financing contract. This long-standing collaboration represents our commitment to supporting innovative and sustainable environmental projects over the long term. After seven years of fruitful collaboration with Europlasma, this new contract once again illustrates the success of our joint efforts. Europlasma embodies a French industrial flagship and an unparalleled global reference in its sector. We are all fully committed to establishing this collaboration on a lasting basis and to maintain the positive momentum that has been built in recent years.”
Jérôme Garnache-Creuillot, CEO Europlasma :
"I would like to thank the ABO team who continues to financially support the significant growth of the Europlasma Group. Without this support, the rescue of Forges de Tarbes in 2021 would have been impossible. Today, their expertise is preserved, and they contribute more each day to the production of large caliber shells. ABO’s loyal support, as well as that of the Economic and Social Development Fund and local authorities, enables Europlasma to save Valdunes, the last French manufacturer of train wheels and axles. Thus, thanks to this funding, another French expertise, once again strategic, is preserved."
About Alpha Blue Ocean:
Established in 2017, Alpha Blue Ocean is a pioneering and leading player in alternative finance in Europe and worldwide, particularly in the field of medical innovation. In 5 years, the group founded by Pierre Vannineuse has executed over 2 billion euros in financial commitments, 60% of which are in the Healthcare & Innovation sectors.
About EUROPLASMA:
Europlasma is a French group with an international presence, dedicated to designing and developing expertise for the benefit of humanity and the environment. A specialist in depollution, its innovative solutions are aimed at the treatment and valorization of hazardous waste using its proprietary technology, the plasma torch, as well as applications for industries concerned with reducing their environmental footprint, through the substitution of fossil fuels or recycling in a circular economy logic.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425028344/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom